Table 2.

Effect of remission in work and activity impairment in patients with RA.

Characteristics	Total Patients, n = 1274		Employed Patients, n = 451
	Activity Impairment		Absenteeism		Presenteeism
	Estimate (95% CI)	p	Estimate (95% CI)	p	Estimate (95% CI)	p
Age, yrs	0.01 (−0.06 to 0.08)	0.83	0.00 (−0.08 to 0.08)	0.99	−0.14 (−0.27 to −0.02)	0.02
Female	3.69 (1.06−6.33)	< 0.01^*	−0.36 (−2.65 to 1.93)	0.76	2.03 (−1.76 to 5.81)	0.29
RA disease duration	0.87 (−0.62 to 2.35)	0.25	−0.15 (−1.56 to 1.25)	0.76	−0.01 (−2.30 to 2.28)	0.99
Comorbidities positivity	0.77 (−1.39 to 2.94)	0.48	1.65 (−4.02 to 0.72)	0.17	2.08 (−1.82 to 5.97)	0.30
Pain VAS	0.41 (0.35−0.47)	< 0.01^*	−0.03 (−0.10 to 0.03)	0.34	0.22 (0.12−0.33)	< 0.01^*
DAS28 remission	−2.97 (−5.13 to −0.81)	< 0.01^*	−1.27 (−3.49 to 0.96)	0.26	−4.20 (−7.87 to −0.54)	0.03^*
EQ-5D	−58.71 (−65.15 to −52.27)	< 0.01^*	−11.98 (−18.28 to −5.68)	< 0.01^*	−54.79 (−65.08 to −44.50)	< 0.01^*
Medication use
Methotrexate	0.46 (−1.58 to 2.50)	0.66	1.58 (−0.59 to 3.84)	0.15	4.06 (0.51–7.62)	0.03^*
Other csDMARD	1.38 (−1.13 to 3.89)	0.28	0.15 (−2.61 to 2.90)	0.92	2.95 (−1.53 to 7.43)	0.20
Biologic agents	3.57 (1.60–5.54)	< 0.01^*	0.23 (−1.71 to 2.16)	0.82	2.13 (−1.04 to 5.30)	0.19
Oral corticosteroid	5.71 (3.10–8.32)	< 0.01^*	−1.09 (−4.13 to 1.96)	0.48	3.34 (−1.58 to 8.25)	0.18

↵* p < 0.05. RA: rheumatoid arthritis; VAS: visual analog scale; DAS28: Disease Activity Score in 28 joints; csDMARD: conventional synthetic disease-modifying antirheumatic drugs.